Prostate Cancer and Prostatic Diseases: From the Editor
1-20 of 26 Next
Understanding Competing Risks for Mortality Among Men with Nonmetastatic Castration-Resistant Prostate Cancer
Recent phase 3 trials suggest that both apalutamide, enzalutamide, and darolutamide can delay metastasis-free survival (MFS) significantly in such men with M0 CRPC who have rapid PSA doubling times (<10 mo) and an elevated PSA of 2.0 or higher. These men may have disease in their prostates or regional nodal
The Association of Gleason Score and Tumor Stage in the Prevalence of DNA Repair Gene Mutations in Localized Prostate Cancer
A straight forward hypothesis is that these mutations have prognostic significance, i.e. mutations in pivotal cancer pathways are associated with clinical-, pathological stage, and grade, which in turn are a good proxy/surrogate for the outcome of the disease. Marshall and colleagues1 focussed on DNA repair gene mutations and ‘mined’ existing DNA sequencing information (TCGA, NatureGenetics via cBioportal) to test this hypothesis. There appeared to be a clear correlation between pathological stage (pT3/4 versus pT2) and Gleason Grade groups (GG ≥ 3 versus GG 1-2). In the cT≥3 ánd GG ≥3 tumors in >20% DNA repair gene mutations were identified. Interestingly there appeared
Endoscopic Enucleation of the Prostate
There have been systematic reviews and meta-analyses evaluating individual energy sources to perform EEP versus transurethral resection of the prostate (TURP). The study by Zhang and colleagues is novel in that for the first time, we have an analysis that takes the stance that all of the EEP techniques are essentially equivalent, and therefore creating a very powerful comparison with TURP.
Statins in Prostate Cancer and the Relationship in Men Undergoing Active Surveillance
Given the presumed importance of cholesterol in cancer pathways (it is the precursor for androgens as well as important in cell signaling pathways), there are multiple reasons to believe statins have anti-prostate cancer properties. While multiple studies have examined the role of statins in prostate cancer, often with mixed results, no prior study has examined this relationship in men undergoing active surveillance.
Prostatic Urethral Lift (PUL) for Treating Lower Urinary Tract Symptoms - Results of the MedLift Study
Other than OML status, the inclusion criteria for MedLift were identical to L.I.F.T.: ≥ 50 years of age, International Prostate Symptom Score (I-PSS) ≥ 13, and Qmax ≤ 12 ml/s. The primary endpoints were an improvement in I-PSS over baseline and incidence of post-procedure complications. Outcomes were compared to the L.I.F.T. historical cohort.
Thromboembolic Events Associated with ADT Treatment in Prostate Cancer Patients
Prostate Cancer Risk by Lipid Parameters
From the Desk of the Associate Editor: The Diverse Use of PET/CT Diagnostic Imaging for Prostate Cancer
From the Desk of the Associate Editor: The Relationship of the B7H3 Immune Checkpoint to Prostate Cancer Outcomes
From the Desk of the Associate Editor: Utility of a PrCa Urinary Biomarker in Active Surveillance
From the Desk of the Associate Editor: PSMA PET/CT in the Assessment of Intra-Prostatic Prostate Cancer
From the Desk of the Editor: Obesity is Linked to High-Grade Prostate Cancer
From the Desk of the Associate Editor: Revisiting Neoadjuvant ADT Prior to Prostatectomy
From the Desk of Andrew Armstrong - Use of Biopsy-based Genomic Classifier to Predict Distant Metastasis.
From the Desk of the Associate Editor: Prostate Cancer Radiation and Urethral Strictures: A Systematic Review and Meta-analysis
From the Desk of the Editor: Saturated Fat Intake and Prostate Cancer Aggressiveness
From the Desk of the Associate Editor: Is Active Surveillance a Suitable Option for African American Men with Prostate Cancer?
These investigators undertook a systematic review of studies of AA men with low-risk prostate cancer and AS. They identified eleven studies focused on pathologic features at time of surgery and five on other clinical outcomes. Further, they reviewed genetic characteristics of prostate cancer and the AA population. They did not
From the Desk of the Associate Editor: Progression on Enzalutamide: Data from the PREVAIL Trial
From the Desk of the Associate Editor: Blood-based and Urinary Prostate Cancer Biomarkers: A Review and Comparison of Novel Biomarkers for Detection and Treatment Decisions
From the Desk of the Editor: Meta-analysis of Metabolic Syndrome and Prostate Cancer
1-20 of 26 Next